RIPCIN study: Remote Ischemic Preconditioning to reduce Contrast-Induced Nephropathy

Remote Ischemic Preconditioning to reduce Contrast-Induced Nephropathy: a blinded randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN76496973

Enrollment

Registered

2013-02-27

Start date

2012-10-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-induced nephropathy Urological and Genital Diseases Contrast-induced nephropathy

Interventions

The researcher performs the sham preconditioning or ischemic preconditioning procedure. RIPC will be applied by 4 cycles of 5 minutes inflation and 5 minutes deflation of a standard blood pressure c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Interventions with expected intravascular contrast volume > 100 mL: 1.1. Thoracic Endovascular Aortic Repair (TEVAR) 1.2. Endovascular Aortic Repair (EVAR) 1.3. Digital Substraction Angiography (DSA) 1.4. Percutaneous Transluminal Angioplasty (PTA) 1.5. Percutaneous Intentional Endovascular Revascularisation (PIER) 1.6. Carotic Artery Stenting (CAS) 1.7. Percutaneous coiling/embolisation procedures 1.8. Computed Tomographic Angiography 2. High-risk of CIN (according CBO guideline): 2.1. eGFR 75 years, anaemia (Ht 18 years (no upper limit)

Exclusion criteria

Exclusion criteria: 1. Age < 18 years 2. Hemo- and peritoneal dialysis 3. Concomitant inclusion in another interventional study 4. Percutaneous coiling/embolisation procedures of the kidney

Design outcomes

Primary

Measure	Time frame
Current primary outcome measures as of 14/04/2014: Change in serum creatinine levels from baseline (day prior to contrast administration) to 48-72 hours after contrast administration Previous primary outcome measures: Change in serum creatinine levels from baseline (day prior to contrast administration) to 48 hours after contrast administration	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 14/04/2014: 1. Change in biomarkers (for kidney injury) levels in blood and urine from baseline to 4-6 hours after contrast administration. 2. Incidence of CIN (>25% and/or 0.5 mg/dL rise in serum creatinine) 3. Death, rehospitalization and/or hemodialysis within 6 weeks after contrast-administration Previous secondary outcome measures: 1. Change in biomarkers (for kidney injury) levels in blood and urine from baseline to 24 and/or 48 hours after contrast administration. 2. Incidence of CIN (>25% rise in serum creatinine) 3. Death, rehospitalization and/or hemodialysis within 6 weeks after contrast-administration	—

Measure

Time frame

Current secondary outcome measures as of 14/04/2014: 1. Change in biomarkers (for kidney injury) levels in blood and urine from baseline to 4-6 hours after contrast administration. 2. Incidence of CIN (>25% and/or 0.5 mg/dL rise in serum creatinine) 3. Death, rehospitalization and/or hemodialysis within 6 weeks after contrast-administration Previous secondary outcome measures: 1. Change in biomarkers (for kidney injury) levels in blood and urine from baseline to 24 and/or 48 hours after contrast administration. 2. Incidence of CIN (>25% rise in serum creatinine) 3. Death, rehospitalization and/or hemodialysis within 6 weeks after contrast-administration

—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 17, 2026